A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report
about
The therapeutic potential of targeting the PI3K pathway in pediatric brain tumorsA phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors.The effect of forced expression of mutated K-RAS gene on gastrointestinal cancer cell lines and the IGF-1R targeting therapy.Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group.
P2860
A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A Phase I Study of Cixutumumab ...... roup Phase I Consortium Report
@ast
A Phase I Study of Cixutumumab ...... roup Phase I Consortium Report
@en
type
label
A Phase I Study of Cixutumumab ...... roup Phase I Consortium Report
@ast
A Phase I Study of Cixutumumab ...... roup Phase I Consortium Report
@en
prefLabel
A Phase I Study of Cixutumumab ...... roup Phase I Consortium Report
@ast
A Phase I Study of Cixutumumab ...... roup Phase I Consortium Report
@en
P2093
P2860
P50
P1476
A Phase I Study of Cixutumumab ...... roup Phase I Consortium Report
@en
P2093
Alexander A Vinks
Brenda Weigel
Charlotte Ahern
Darcy A Krueger
George Thomas
Helen Chen
Joel M Reid
John P Perentesis
L Austin Doyle
Lars M Wagner
P2860
P304
P356
10.1158/1078-0432.CCR-14-0595
P407
P577
2014-12-02T00:00:00Z